{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:55:30Z","timestamp":1789772130903,"version":"4.0.1"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,5,1]]},"DOI":"10.2169\/internalmedicine.2429-23","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:52:52Z","timestamp":1694731972000},"page":"1261-1267","source":"Crossref","is-referenced-by-count":11,"title":["Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer"],"prefix":"10.2169","volume":"63","author":[{"given":"Takaaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"},{"name":"Center for Clinical Oncology, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Higo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[{"name":"Center for Innovative Clinical Medicine, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tabata","sequence":"additional","affiliation":[{"name":"Center for Clinical Oncology, Okayama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4: 1721-1728, 2018."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39: 3978-3992, 2021.","DOI":"10.1200\/JCO.21.01992"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Holtzman NG, Xie H, Bentzen S, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol 23: 112-121, 2021.","DOI":"10.1093\/neuonc\/noaa183"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. de Groot PM, Arevalo O, Shah K, et al. Imaging primer on chimeric antigen receptor T-cell therapy for radiologists. Radiographics 42: 176-194, 2022.","DOI":"10.1148\/rg.210065"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Fron Pharmacol 11: 557, 2020.","DOI":"10.3389\/fphar.2020.00557"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34: 45-55, 2019.","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yomota M, Mirokuji K, Sakaguchi M, et al. Cytokine release syndrome induced by immune-checkpoint inhibitor therapy for non-small-cell lung cancer. Intern Med 60: 3459-3462, 2021.","DOI":"10.2169\/internalmedicine.5922-20"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guha-Thakurta N, Wierda WG. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy. Neurology 91: 843, 2018.","DOI":"10.1212\/WNL.0000000000006436"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gao Y, Pan J, Shen D, et al. Immune checkpoint inhibitor associated autoimmune encephalitis, rare and novel topic of neuroimmunology: a case report and review of the literature. Brain Sci 12: 773, 2022.","DOI":"10.3390\/brainsci12060773"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer 6: 56, 2018.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Aldea M, Orillard E, Mansi L, et al. How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer 141: 239-251, 2020.","DOI":"10.1016\/j.ejca.2020.09.032"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016: 567-572, 2016.","DOI":"10.1182\/asheducation-2016.1.567"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ohira J, Kawamoto M, Sugino Y, Kohara N. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine 99: e19741, 2020.","DOI":"10.1097\/MD.0000000000019741"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 37: 48-52, 2019.","DOI":"10.1002\/hon.2595"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7: 1404-1419, 2017.","DOI":"10.1158\/2159-8290.CD-17-0698"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/9\/63_2429-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T03:29:14Z","timestamp":1714793354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/9\/63_2429-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2429-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"article-number":"2429-23"}}